First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

Siow Ming Lee; Iftekhar Khan; Sunil Upadhyay; Conrad Lewanski; Stephen Falk; Geraldine Skailes; Ernie Marshall; Penella J Woll; Matthew Hatton; Rohit Lal; Richard Jones; Elizabeth Toy; David Chao; Gary Middleton; Sue Bulley; Yenting Ngai; Robin Rudd; Allan Hackshaw; Chris Boshoff

doi:10.1016/S1470-2045(12)70412-6

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

Siow Ming Lee, Iftekhar Khan, Sunil Upadhyay, Conrad Lewanski, Stephen Falk, Geraldine Skailes, Ernie Marshall, Penella J Woll, Matthew Hatton, Rohit Lal, Richard Jones, Elizabeth Toy, David Chao, Gary Middleton, Sue Bulley, Yenting Ngai, Robin Rudd, Allan Hackshaw, Chris Boshoff

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

132 Citations (Scopus)

Abstract

Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves clinical outcome in these patients.

Original language	English
Pages (from-to)	1161-70
Number of pages	10
Journal	The Lancet Oncology
Volume	13
Issue number	11
DOIs	https://doi.org/10.1016/S1470-2045(12)70412-6
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(12)70412-6

Cite this

Lee, S. M., Khan, I., Upadhyay, S., Lewanski, C., Falk, S., Skailes, G., Marshall, E., Woll, P. J., Hatton, M., Lal, R., Jones, R., Toy, E., Chao, D., Middleton, G., Bulley, S., Ngai, Y., Rudd, R., Hackshaw, A., & Boshoff, C. (2012). First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 13(11), 1161-70. https://doi.org/10.1016/S1470-2045(12)70412-6

@article{9b588623c8da44d3a89f46a92fffa691,

title = "First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial",

abstract = "Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves clinical outcome in these patients.",

author = "Lee, {Siow Ming} and Iftekhar Khan and Sunil Upadhyay and Conrad Lewanski and Stephen Falk and Geraldine Skailes and Ernie Marshall and Woll, {Penella J} and Matthew Hatton and Rohit Lal and Richard Jones and Elizabeth Toy and David Chao and Gary Middleton and Sue Bulley and Yenting Ngai and Robin Rudd and Allan Hackshaw and Chris Boshoff",

year = "2012",

doi = "10.1016/S1470-2045(12)70412-6",

language = "English",

volume = "13",

pages = "1161--70",

journal = "The Lancet Oncology",

publisher = "Elsevier",

number = "11",

}

Lee, SM, Khan, I, Upadhyay, S, Lewanski, C, Falk, S, Skailes, G, Marshall, E, Woll, PJ, Hatton, M, Lal, R, Jones, R, Toy, E, Chao, D, Middleton, G, Bulley, S, Ngai, Y, Rudd, R, Hackshaw, A & Boshoff, C 2012, 'First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, vol. 13, no. 11, pp. 1161-70. https://doi.org/10.1016/S1470-2045(12)70412-6

TY - JOUR

T1 - First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL)

T2 - a double-blind, placebo-controlled, phase 3 trial

AU - Lee, Siow Ming

AU - Khan, Iftekhar

AU - Upadhyay, Sunil

AU - Lewanski, Conrad

AU - Falk, Stephen

AU - Skailes, Geraldine

AU - Marshall, Ernie

AU - Woll, Penella J

AU - Hatton, Matthew

AU - Lal, Rohit

AU - Jones, Richard

AU - Toy, Elizabeth

AU - Chao, David

AU - Middleton, Gary

AU - Bulley, Sue

AU - Ngai, Yenting

AU - Rudd, Robin

AU - Hackshaw, Allan

AU - Boshoff, Chris

PY - 2012

Y1 - 2012

N2 - Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves clinical outcome in these patients.

AB - Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves clinical outcome in these patients.

U2 - 10.1016/S1470-2045(12)70412-6

DO - 10.1016/S1470-2045(12)70412-6

M3 - Article

C2 - 23078958

VL - 13

SP - 1161

EP - 1170

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 11

ER -

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this